Author:
Wang X.,Ren J.,Zhang J.,Yan Y.,Jiang N.,Yu J.,Di L.,Song G.,Che L.,Jia J.,Zhou X.,Yang H.,Lyerly H. K.
Funder
Beijing Municipal Science and Technology Project
National Natural Science Foundation of China (CN)
Beijing Oncological Leadership Grant
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference35 articles.
1. Shastry M, Yardley DA. Updates in the treatment of basal/triple-negative breast cancer. Curr Opin Obstet Gynecol. 2013;25(1):40–8.
2. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple negative, node negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node negative breast cancer. J Clin Oncol. 2010;28:2966–73.
3. Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, et al. Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. Clin Breast Cancer. 2015;. doi: 10.1016/j.clbc.2015.03.002 .
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献